Stellantis CFO praises new CEO, promises progress in American market at fireside chat
Stellantis CFO Doug Ostermann spent the afternoon praising the automaker's new chief executive and promising big things for the American operations of the company in years to come.
Speaking at the Bernstein Strategic Decisions Conference on May 29, an economic conference aimed at company executives and investors, Ostermann touched on an array of issues: How will Stellantis keep up with the blazing pace of Chinese automakers? How will the company address headwinds brought on by President Donald Trump's tariff policies?
But to open the 50-minute discussion, Ostermann took a moment to praise Antonio Filosa, who was named the next CEO of Stellantis on May 28.
"Antonio has, you know, kind of this proven track record of improving things, building things, getting at issues and being very hands-on," Ostermann said, pointing to his work in North and South America, where Jeep dominated South American markets under Filosa's guidance.
"In the short time that he's been the head of North America, he fixed what was a significant inventory problem, adjusted pricing, built back the relationships with dealers," Ostermann said. "He's always been a man with a plan."
Filosa, a self-described protégé of the late charismatic Fiat Chrysler leader Sergio Marchionne, is tasked with reviving a company that has lagged financially in the last several years. Under former CEO Carlos Tavares, Stellantis saw a 70% drop in net profit between 2023 and 2024. The struggles continued into 2025, as Stellantis' profits slid 14% in its first quarter of 2025.
Ostermann, who has been with Stellantis-affiliated brands for eight years, says he trusts Filosa to lead the automaker out of the rough years.
Stellantis names new CEO: Meet Antonio Filosa, the new CEO of Stellantis and protégé of Sergio Marchionne
Fixing Model T's: Hot job? A growing field for mechanics who can fix Ford Model T's and antique cars
Stellantis is an international company, managing 14 brands including Chrysler, Dodge, Jeep, Ram, Fiat and several names in the European market. American dealers and factory workers have previously scolded the company for leaving American operations behind.
With the compounding influence of a new leader in Filosa, who previously told the Free Press the United States is "the biggest priority" for Stellantis, and tariff policies seeking to reward automotive production in the United States, Ostermann said that he anticipates the company putting more focus on American production and jobs.
Ostermann noted that several new models will be rolling out this year, including a midsize truck under the Ram banner and a retooled Jeep Cherokee on a hybrid powertrain, set to be released in the back half of 2025.
The new Cherokee comes two years after the model was canceled in 2023, and Ostermann said it will be Stellantis' first vehicle with a full hybrid powertrain.
Along with the new Cherokee, Ostermann mentioned Ram's upcoming foray into the midsize truck market — a segment in which Stellantis does not currently offer a vehicle. Plans for the new truck and other manufacturing, Ostermann said, are being made with tariffs in mind.
"Clearly, we're going to be more biased toward the U.S. manufacturing going forward," Ostermann said, when asked how the brand is adjusting to proposed tariffs. "When we look at the opportunities that we have to get into, say, the midsize truck segment ... we have a natural space there with the Ram brand."
He followed up, indicating plans are moving forward to build the truck in America.
"I'm sure we will industrialize (the midsize truck) in the United States," Ostermann said. "Our intent, you know, going forward, and always, for the most part, has been to produce where we sell."
The new CEO, Filosa, officially assumes control of the company on June 23, when he will be tasked with maintaining his record of improving things for the struggling automaker.
Liam Rappleye covers Stellantis and the UAW for the Detroit Free Press. Contact Liam Rappleye: LRappleye@freepress.com
This article originally appeared on Detroit Free Press: Stellantis CFO says tariffs will bring more focus from company to U.S.
Errore nel recupero dei dati
Effettua l'accesso per consultare il tuo portafoglio
Errore nel recupero dei dati
Errore nel recupero dei dati
Errore nel recupero dei dati
Errore nel recupero dei dati
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
39 minutes ago
- The Hill
Puerto Rico is Trump's perfect partner in reshoring
President Trump recently signed an executive order to bring pharmaceutical manufacturing back to the U.S. by streamlining the process for the Food and Drug Administration to approve pharmaceutical manufacturing plants. This is the latest in the Trump administration's agenda to protect national security and create American jobs by promoting the reshoring of critical supply chains that Americans rely on every day. These efforts are coupled with international tariffs to encourage domestic manufacturing. Reshoring pharmaceutical manufacturing is not only dire for American national security, but it could have resounding economic impacts across the country. One U.S. jurisdiction that is ready and in a perfect position to partner in this effort is Puerto Rico, where pharmaceutical manufacturing is already a more than $50 billion industry. With complementary efforts underway in Congress and on the island, the White House should look to Puerto Rico as America's pharmaceutical powerhouse while not trapping the island in its current territory status by hindering a future transition to statehood that would further boost the island's manufacturing ability. As a territory, the island is part of the U.S. customs zone and is not subject to U.S. tariffs, and everything that is made in Puerto Rico is 'Made in the USA.' Yet, that same territory status has limited Puerto Rico's economic development by creating persistent uncertainty, underinvestment and an unequal playing field for economic competition. The territory status is unpopular on the island, and Puerto Rican voters have voted in favor of statehood four consecutive times, most recently last November. Trump and Congress have the opportunity of a generation to leverage the pharmaceutical infrastructure and workforce in Puerto Rico to achieve their agenda while also turbocharging the economy on the island, and they have the perfect ally in Puerto Rico to do it with — the island's Republican Gov. Jenniffer González-Colón. González-Colón is leading an ambitious agenda to reshape the national narrative about the island and its people — and ultimately achieve statehood for Puerto Rico. Aligning with the Trump administration's vision to reshore advanced manufacturing of critical products, she issued an executive order in late March and reached out to top White House officials to offer Puerto Rico's well-established, yet currently underutilized, manufacturing capacity as an economic engine to help grow American prosperity. González-Colón's executive order promotes the relocation of overseas manufacturing of pharmaceuticals and other products to Puerto Rico. Much like Trump's executive order, it eliminates barriers and streamlines the process for businesses to move to the island. This action is complementary to the Medical Manufacturing, Economic Development and Sustainability Act, which was recently reintroduced and incentivizes pharmaceutical manufacturing on the island and throughout economically distressed zones across the United States. The bill is designed to attract business to the island in a way that invests in the people of Puerto Rico. It does this by providing an incentive for medical manufacturing facilities to relocate to economically distressed zones, with an incentive dependent on the number of jobs created to ensure money is flowing back into communities. The incentive itself is based on economic factors and applies to communities throughout the United States — an appropriately wide scope that comports with Trump's strong desire to reshore large amounts of production in a short time frame. By tethering the tax credits to what manufacturers invest directly into wages, salaries and real middle-class benefits, the proposal creates good-paying, quality American jobs. Reshoring to Puerto Rico would mean that critical pharmaceuticals and medical devices, as well as other products that are currently manufactured overseas in China and other nations, would now be produced in America. This would create thousands of well-paying manufacturing jobs that Puerto Rico needs to turbocharge the modest economic progress it's made in recent years. The increased consumer demand on the island would help boost the approximately $70 billion in annual interstate commerce, resulting in more jobs and profits stateside. Puerto Rico is a natural partner in reshoring the medical and pharmaceutical manufacturing industry within U.S. borders. The island's leaders share in the White House's vision of a more prosperous pharmaceutical manufacturing industry and are working to ensure reshoring efforts do not trap Puerto Rico in its current territory status but instead enable it to reach its full potential as an engine of economic growth and prosperity as a future state of our Union. Manufacturing makes America stronger, especially when it lifts up communities and the hard-working American citizens that make 'Made in the USA' a possibility, including those in Puerto Rico.
Yahoo
an hour ago
- Yahoo
Cooper Companies Second Quarter 2025 Earnings: EPS Misses Expectations
Revenue: US$1.00b (up 6.3% from 2Q 2024). Net income: US$87.7m (down 1.3% from 2Q 2024). Profit margin: 8.7% (down from 9.4% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: US$0.44 (down from US$0.45 in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 39%. Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are down 13% from a week ago. While earnings are important, another area to consider is the balance sheet. See our latest analysis on Cooper Companies' balance sheet health. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Epoch Times
2 hours ago
- Epoch Times
Dutch Defense Minister Warns of Escalating Chinese Spy Operations
Dutch Defence Minister Ruben Brekelmans warned Saturday that Chinese cyber espionage targeting the Netherlands is intensifying, with the Chinese Communist Party (CCP) particularly focused on stealing advanced semiconductor technology. 'The semiconductor industry, which we are technologically leading—or technology advanced, of course—to get that intellectual property, that's interesting to China,' Brekelmans told Reuters on the sidelines of the Shangri-La Dialogue security forum in Singapore on May 30.
